Clinical trials recruiting for Triple-negative breast cancer
138
Recruiting trials
46
US states with sites
41
Countries
1%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 21 |
| Cyclophosphamide | 11 |
| Carboplatin | 10 |
| Capecitabine | 9 |
| Paclitaxel | 9 |
| Bevacizumab | 5 |
| Sacituzumab govitecan | 5 |
| Camrelizumab | 3 |
| Docetaxel | 3 |
| Epirubicin | 3 |
| Fludarabine | 3 |
| Olaparib | 3 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 27 |
| Florida | 26 |
| Texas | 24 |
| New York | 22 |
| Massachusetts | 16 |
| Virginia | 16 |
| Tennessee | 15 |
| Illinois | 14 |
| Michigan | 14 |
| Colorado | 13 |
| North Carolina | 12 |
| Ohio | 12 |
Top cities
Houston, Texas 18New York, New York 17Boston, Massachusetts 16Fairfax, Virginia 14Nashville, Tennessee 13Chicago, Illinois 12Los Angeles, California 12San Antonio, Texas 11Tampa, Florida 10Dallas, Texas 9
Self-screener
Recruiting trials
- 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- A Multicenter Cancer Biospecimen Collection Study
- A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
- A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4175408 in Participants With Advanced Cancer
- A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
- A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
- A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
- A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
- A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
- A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
- Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
- Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
- An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
- BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
- Breast Cancer Evolution During Neoadjuvant Systemic Therapy
- Breast Cancer PSMA PET
- CTS2190 Phase I /II Clinical Study in Patients
- Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
- Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
- De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
- Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
- Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
- Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)
- Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
- Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- JS207 Combination Therapy in Triple-negative Breast Cancer
- LAG3 Expression in Triple Negative Breast Cancer
- Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- MicroRNA Profiles in Triple Negative Breast Cancer
- Microbiome Immunotherapy Neoadjuvant Assessment
- Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
- Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
- Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
- NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- PRE-ISPY Phase I/II Oncology Platform Program
- Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
- Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
- Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
- Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
- Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Related conditions
Trials recruiting for Triple-negative breast cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Non-small cell lung cancer 507Colorectal cancer 1359Pancreatic cancer 870Head and Neck Squamous Cell Carcinoma 42Ovarian cancer 118Melanoma 487Endometrial cancer 68Solid Tumor, Adult 38
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Triple-negative breast cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.